GlassScriptPhysician profile
Shawn George
NPI 1174150403
$3,237.60
in general payments reported to CMS, 2019-2025
24 companies · $1,552 in 2025
The $1,552 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.71 · 2023: $284 · 2024: $1,380 · 2025: $1,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,147 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,146.90 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $569.29 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $505.73 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $487.70 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Sumitomo Pharma America, INC. | $290.94 | 2024-2025 | Myfembree, Gemtesa |
| Amgen INC. | $206.62 | 2024-2025 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $206.23 | 2024-2025 | Veozah |
| Dexcom, INC. | $147.18 | 2023-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $142.92 | 2024-2025 | |
| Exact Sciences Corporation | $94.17 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $91.35 | 2024-2025 | Zepbound, Mounjaro |
| Biogen, INC. | $72.61 | 2025 | Zurzuvae, Spinraza |
| Otsuka America Pharmaceutical, INC. | $69.84 | 2024-2025 | Rexulti |
| Exeltis, USA INC. | $63.79 | 2024-2025 | Slynd |
| Coopersurgical, INC. | $49.37 | 2023-2025 | Paragard T 380a, Paragard T 380a |
| Medtronic, INC. | $43.52 | 2025 | Inceptiv |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $42.75 | 2024 | Flucelvax, Fluad |
| Laborie Medical Technologies Corp. | $24.68 | 2024 | Goby |
| Axsome Therapeutics, INC. | $24.63 | 2024 | Auvelity |
| Xeris Pharmaceuticals, INC. | $23.42 | 2024 | Gvoke Hypopen |
| Boston Scientific Corporation | $21.71 | 2020 | |
| Echosens North America, INC. | $16.17 | 2025 | Fibroscan |
| Lundbeck LLC | $15.39 | 2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.78 | 2024 | Xifaxan |
| Ibsa Pharma INC. | $12.81 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.